The phase 3 Keynote-061 trial assessing Keytruda as a second-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma did not achieve its primary endpoint of
The drug-discovery partnership, which will last for five-years, will be focused on Messenger RNA (mRNA) translation. According to Cancer Research UK, mRNA translation, which is the cellular process of assembling proteins,
The reductions in jobs, which will be carried out over the next two years, represent over 25% of the company's total workforce. Teva’s restructuring plan aims to cut down
IXIFI is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor. The drug has now been indicated in the US for the treatment of patients having rheumatoid
The approval has been granted for lyophilized Oncaspar as a component of antineoplastic combination therapy to treat ALL in pediatric patients from birth to 18 years and adult
The late-stage study, dubbed MURANO, demonstrated that Venclexta/Venclyxto, an oral B-cell lymphoma-2 (BCL-2) inhibitor in combination with MabThera/Rituxan cut down the risk of disease progression or death by 83%
Alzheimer’s Clinical Trial Consortium (ACTC), which covers 35 sites across the US, will engage in the development of new and effective ways to treat Alzheimer’s related disorders. The
The approval from the drug regulator covers adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.
Ramucirumab, which is an antiangiogenic therapy, was evaluated in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) for the treatment of HER2-negative metastatic gastric or gastroesophageal junction (GEJ)
The study demonstrated that the Tecentriq combination has more effectively reduced the disease progression in patients compared to those who received Avastin plus chemotherapy. IMpower150 is a multicenter,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.